ReviewClinical pediatrics2026
Pathogenesis, Treatment Advances, and Renal Outcomes in Childhood-Onset Lupus Nephritis.
Review in Clinical pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus is defined as an autoimmune and inflammatory disease that is distinguished by the involvement of diversified multisystem and a persistent course with unpredictable flares. Immune complex-mediated glomerulonephritis is the main presentation of renal involvement and is commonly regarded as lupus nephritis (LN). Although the long-term renal prognosis has been considerably improved, a significant morbidity and mortality is still experienced by children and adolescents with LN. Furthermore, present literature is insufficient with regard to data related to pediatrics, resulting in clinicians to depend entirely on therapeutic approaches employed for adults. Treatment protocols have been produced by various international groups that recommend an intense duration of immunosuppression to stop the process of acute renal inflammation, with subsequent maintenance therapy and close monitoring for disease improvement and rapid assessment of disease flares. Prevalence of renal remission is suboptimal indicating only 40% to 60% of patients attaining complete remission. The rate of chronic kidney disease (CKD) stage V has been observed to be at least 15% and the presence of LN has an association with high mortality rates. In ascertained renal failure, renal transplantation is implied to be the most favorable modality of renal replacement therapy in this specific patient group. This review aims to describe childhood-onset LN and provide an overview on the pathogenesis, therapeutic approaches, emerging therapies and present renal outcomes for this disease with the objective of recognizing the key features that might aid in reducing the risk of long-term CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.